HCPCS Level II code J7318 identifies Durolane, a hyaluronan derivative, billed per 1 mg for intra-articular injection. The code is used to report viscosupplementation procedures intended to relieve joint pain through intra-articular administration of a single-dose hyaluronan product. Nationally, use of this code reflects utilization of non-opioid, procedure-based management for osteoarthritis and other joint conditions, with implications for outpatient practice workflows, payer coverage policies, and supply-chain considerations.

Key payers in this national analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context for viscosupplementation, common sites of service where J7318 is billed, and an outline of the billing and coding considerations relevant to this HCPCS Level II code. The publication also covers benchmarking and reimbursement context where available, recent policy developments that affect coverage and prior authorization, and practical notes on documentation requirements tied to intra-articular injection services.

This summary is intended to help billing managers, clinicians, and policy analysts quickly understand the role of HCPCS Level II code J7318 in outpatient musculoskeletal care and payer interactions. Data not available in the input is noted where applicable.